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1. Introduction
  Toxoplasmosis is a common infection of human and 
animals. The disease has a worldwide distribution. The 
prevalence of infection varies among geographic regions[1]. 
About 30% of the world’s population are estimated to 
be infected, most of whom experience no overt disease 
symptoms[2]. The infection is caused by the intracellular 
protozoan parasite, Toxoplasma gondii(T.gondii)[3]. 
The disease can be congenital or acquired postnataly. 
Immunocompetent persons with primary infection 
are usually asymptomatic. It has a variety of clinical 
manifestations that may range from a subclinical course to a 
generalized infection with fatal outcome[4].
  Toxoplasmosis is one of the most common pathogens 
to cause intraocular inflammation and chorioretinitis, 
accounting for 30-50% of all cases of posterior uveitis 
in the United States[5]. In a large-population based 
household study in southern Brazil, the incidence of ocular 
toxoplasmosis was 18%, which is extremely high[6]. Most 
ocular involvement is believed to be due to congenital 
infection (80-98%) and experience reactivation in the 
2nd and 3rd decades that can present with bilateral eye 
involvement. Adults with acquired infection usually present 
with unilateral ocular disease in the absence of prior 
scarring[7].
  The ocular lesions primarily affect the retina. The 
hallmark of ocular toxoplasmosis is a localized necrotizing 
retinitis with inflammation of the subjacent choroid, 
ultimately resulting in characteristic atrophic scars. Lesions 
may be single but are more commonly multiple often in 
small clusters and individual lesions in the cluster may be 
have varied ages[8].
  The ocular manifestations of the disease include sudden 
onset of floaters with blurring of vision, scotoma, pain, 
photophobia, conjunctival hyperemia and epiphora. 
Impairment or a loss of central vision occurs when the 
macula is involved. As inflammation resolves, vision 
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improves, frequently without complete recovery of visual 
acuity. Macular involvement causes loss of central vision[9].
  Typical features of toxoplasma chorioretinitis include 
intensely white focal lesions with an overlying, intense, 
vitreous inflammatory reaction. With healing, the lesions 
become pale, atrophy, and develop black pigment. There 
can also be an associated secondary iridocyclitis and 
increased intraocular pressure[10].
  In reality, the diagnosis of ocular toxoplasmosis has 
remained mainly clinical by ophthalmological examination, 
despite the development of serological and other new tests. 
Serologic tests are positive in a considerable percentage of 
the general population and are not necessarily indicative 
of ocular involvement. On the other hand serum antibody 
titer may not correlate with the presence of active lesions in 
many patients. Diagnosis is supported by good response to 
installed therapy[9].
  Low titers of IgG antibody are usual in patients with active 
chorioretinitis due to reactivation of congenital T. gondii 
infection; IgM antibody titer is usually high in the case of 
acute acquired toxoplasmosis. The conclusive diagnosis of 
active toxoplasmosis depends on the isolation of toxoplasma 
from body fluids or tissues, but this is rarely possible in 
ocular disease[11].
 Ocular toxoplasmosis is a self-limiting disease in 
immunocompetent patients and the lesion usually heals in 
6-8 weeks[12]. Treatment most likely indicated in patients 
with: decrease in visual acuity, macular or peripapillary 
lesions, lesions greater than one optic disk diameter, 
moderate-to-severe vitreous inflammation, multiple active 
lesion and lesions associated with acquired infections. 
Systemic corticosteroids are indicated when lesion involve 
the macula, optic nerve head, or papillomacular bundle[10].  
  The purpose of this study was to investigate clinical 
features, ocular findings, management and follow-up data in 
immunocompetent patients with active ocular toxoplasmosis.
2. Materials and methods
  Between 2001 and 2010, patients with first attack of ocular 
toxoplasmosis that were examined in the Eye Clinics of 
the Semnan University of Medical were enrolled. Only 
immunocompetent patients were included in the study. All 
patients underwent a complete ophthalmic examination 
including slit lamp examination, funduscopy with three-
mirror lens (Goldmann, USA) and indirect ophthalmoscopy. 
  All patients were evaluated by one ophthalmologist. Data 
were recorded for each patient including age, gender, 
clinical presentation, ophthalmic examination finding, 
treatment outcome, and side-effects of drugs. The diagnosis 
of ocular toxoplasmosis was established by acute onset of 
visual symptoms, detecting typical toxoplasmic lesions in 
eye, such as the presence of active, yellow-white, cotton-
like patches with indistinct margins of hyperemia with or 
without a hyperpigmented retinal scar and the detection of 
positive IgG anti-Toxoplasma antibody. Cases with atypical 
clinical features were excluded. Complete blood counts were 
obtained in all patients before treatment. After discussion 
between specialist of infectious disease and ophthalmologist, 
treatment was given to all patients because of the severity 
of disease. Our treatment protocol included pyrimethamine, 
sulfadiazine and folinic acid for 6 weeks. Patients with 
lesions in the macular and papillomacular area or with 
severe vitritis received corticosteroids.
  Patients checked at weekly intervals throughout 
the treatment period for clinical and ophthalmologic 
response and then every three month until one year. Any 
complications in therapy were monitored, and a complete 
blood cell count was performed ones a week. 
  Statistical analyses were performed by Chi-Square test in 
SPSS 16.0 computer software. P value <0.05 was considered 
statistically significant.  
3. Results
  This prospective observational case series included 25 
patients. Of the patients, 13 (52%) were male and 12 (48%) 
were female. Their ages ranged from 13 to 68 years, with the 
mean依SD being (26.8依11.1) years. Seventeen (68%) patients 
were younger than 30 years. The mean依SD time from onset 
of symptoms until diagnosis was (20.0依16.4) days. In 92% 
of patients one eye was involved (48% left and 44% right) 
and only in 8% was bilateral. Lesions were located at the 
peripheral retina in 48%, macula in 28% and at the macula 
and peripheral retina in 24% of the patients. The most 
common presenting symptom was blurred vision (96%), 
followed by eye pain (28%). And 20% had photophobia and 
12% had epiphora.
  Of  these pat ients ,  12 (48%) received systemic 
corticosteroid. Clinical response observed in 44% 2 weeks 
before and in 56% 2 weeks after. A total of 50% patients 
with corticosteroid and 38.5% with others showed clinical 
response 2 weeks before that was not significantly different 
(P=0.561). Complete blood count was within normal limits 
in all patients at the beginning and during the treatment. 
One patient developed glossitis and another had nausea 
and vomiting in first week. Two patients (8%) had visual 
loss in the first year of treatment. None of the patients had a 
recurrence during our follow-up period.
4. Discussion
  Ocular toxoplasmosis is characterized by self-limited 
necrotizing chorioretinitis and vitritis. Chorioretinitisis 
usually is due to reactivation of a congenital infection. 
Most ocular involvement is believed to be due to congenital 
infection, however, recent epidemiologic studies showed 
a higher incidence of acquired ocular toxoplasmosis[13,14]. 
There are some variations in the clinical manifestations of 
ocular toxoplasmosis  in different parts of the world.
  The demographic features of our patients are similar to 
those reported in other large series[15-17]. Our patients’ mean 
age was (26.8依11.1) years and most of the patients (68%) 
were younger than 30 years. In our study also, both sexes 
were equally affected. In Labalette study the distribution of 
females and males was 59% and 41%, respectively[18].
  The disease is uncommon after the age of 50 years. In our 
patients only one patient was older than 50 years.
  Overall ocular toxoplasmosis is bilateral in about 40% of 
patients. Our findings showed that ocular toxoplasmosis 
was unilateral in 92% and bilateral only in 8%. Bilateral 
lesions are more common in the congenital form, while 
the acquired form tends to be unilateral. We did not have 
enough information to determine the frequency of either 
congenital or acquired ocular toxoplasmosis but findings 
show that most patients in our study may be were acquired. 
It has been suggested that in some geographic areas 
acquired infection may account for the majority of cases of 
ocular toxoplasmosis[9, 19]. In a case series of 16 patients, eye 
involvement occures in 9 patients (56.2%) was unilateral[20]. 
In other studies 64.3%[21] and 71%[15] of patients had 
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unilateral involvement. 
  The left and right eye was affected near equally in our 
study. In Labalette study the left eye was affected in 56% of 
patients[18]. 
  In our study, the most common symptom was blurred vision 
(96%), followed by eye pain (28%). Similar observations were 
reported by other authors that blurred vision was the most 
common symptom[20, 22].
  In the present series, lesions were located at the 
peripherals retina in 48%, macula in 28% and at the macula 
and peripherals retina in 24% of the patients. Macular 
involvement was lower in our patients comparing to other 
study. In 65 patients with active disease localization 
of the lesion was the macula in 74%, the macula and 
peripheral retina in 5%, the peripheral retina in 15% 
and the peripapillary retina in 3 (5%)[15]. In a prospective 
longitudinal study lesions were located at the macula in 54% 
of patents[10]. 
  Although the necessity for treatment of ocular 
toxoplasmosis is still controversial, we decided to treat 
all patients considering the location of lesions. Also 12 
patients received corticosteroid. The results of treating were 
satisfactory in all cases. Marked improvement was seen in 
44% of patients during 2 weeks of therapy. In one study 23 
patients with acute toxoplasma chorioretinitis were treated 
with sulfonamides, pyrimethamine and corticosteroids 
for a period of 4 weeks. All patients showed clinical 
improvement within 2 weeks[23]. Although more patients with 
corticosteroid therapy showed clinical response 2 weeks 
before but this difference was not significant comparing with 
those without therapy. Systemic corticosteroid mostly helps 
to prevention of complications.
  The most common complication of ocular toxoplasmosis is 
visual loss because of macular or optic nerve lesions. In our 
study 2 (8%) of patients had this complication. In contrast to 
other study[16,17], this complication rate is low in the present 
series. The difference may be due to exclusion of atypical 
severe cases from our study and treatment of all patients.
  We found no significant adverse drug reaction during 
treatment. In agreement with another study in which 62 
patients were treated with similar regime, only 4 cases 
developed gastrointestinal disturbances[22]. So it is 
concluded that pyrimethamine+sulfadiazine combination is 
safe for treatment of ocular toxoplasmosis.
  There was no recurrence during one year follow-up 
period in our study. This probably does not mean that the 
recurrences will not develop but may be due to short follow 
up time and to the small number of patients. In a study 
10.5% of 19 patients without any preexisting scars at initial 
visit and 26.6% of 90 patients who had scars in at least one 
eye had recurrences. In patients with recurrences, 65.4% 
occurred within two years follow-up period[17].
  In summary, our study supports evidence that active 
ocular toxoplasmosis has no gender predilection and affects 
young individuals in the 2nd and 3rd decades of life. More 
unilateral involvements show that acquired infections is 
increasing. Visual prognosis is good in patients and no 
recurrences during one year follow-up period. It may have 
implications in favor of treatment of all active typical ocular 
toxoplasmosis. 
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